Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The Company is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.44m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttps://sareum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m | 6.14m | 67.00 | -- | -- | -- | -- | -0.0028 | -0.0028 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -190.34 | -146.14 | -433.59 | -169.40 | -- | -- | -- | -- | 0.4766 | -2.42 | -- | -- | -- | -- | -26.15 | -- | -- | -- |
| Talisman Metals PLC | 0.00 | 65.26k | 6.75m | 1.00 | -- | 2.82 | 103.48 | -- | -0.0064 | -0.016 | 0.00 | 0.0373 | 0.00 | -- | -- | 0.00 | 3.15 | -30.40 | 3.64 | -33.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 99.94 | -- | -- | -- |
| OptiBiotix Health PLC | 1.15m | -191.00k | 7.90m | 5.00 | -- | 0.9385 | 564.46 | 6.87 | -0.0018 | -0.0018 | 0.0113 | 0.0815 | 0.134 | 1.93 | 2.88 | 230,200.00 | -2.22 | 17.23 | -2.33 | 17.84 | 45.44 | 50.78 | -16.59 | 189.34 | 3.75 | -- | 0.00 | 94.93 | 35.09 | 3.15 | 11.48 | -- | -- | -- |
| Futura Medical PLC | 7.93m | -6.29m | 8.14m | 12.00 | -- | 1.40 | -- | 1.03 | -0.0207 | -0.0207 | 0.0261 | 0.01 | 1.06 | 137.36 | 8.58 | -- | -84.19 | -45.00 | -112.42 | -71.79 | 70.67 | -- | -79.41 | -108.25 | 2.21 | -- | 0.00 | -- | 349.09 | 237.55 | 119.85 | -- | 121.02 | -- |
| IXICO PLC | 6.53m | -1.65m | 9.50m | 79.00 | -- | 0.8093 | -- | 1.45 | -0.0186 | -0.0186 | 0.073 | 0.1267 | 0.5222 | -- | 3.18 | 82,708.86 | -13.19 | -3.47 | -15.43 | -4.03 | 48.71 | 55.52 | -25.27 | -6.21 | -- | -- | 0.015 | -- | 13.32 | -7.27 | 17.49 | -- | -5.30 | -- |
| Genflow Biosciences PLC | 0.00 | -1.80m | 10.36m | 5.00 | -- | -- | -- | -- | -0.005 | -0.005 | 0.00 | -0.0007 | 0.00 | -- | -- | 0.00 | -197.92 | -- | -648.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.68 | -- | -- | -- |
| Solvonis Therapeutics PLC | 0.00 | -2.60m | 17.70m | -- | -- | 2.22 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -44.49 | -- | -54.32 | -- | -- | -- | -- | -- | -- | -645.25 | 0.011 | -- | -100.00 | -- | 53.62 | -- | -- | -- |
| Fusion Antibodies PLC | 1.60m | -1.47m | 19.69m | 24.00 | -- | 24.66 | -- | 12.34 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
| Sareum Holdings Plc | 0.00 | -4.44m | 23.47m | 5.00 | -- | 10.04 | -- | -- | -0.0365 | -0.0365 | 0.00 | 0.0169 | 0.00 | -- | -- | 0.00 | -126.85 | -93.37 | -202.14 | -118.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.77 | -- | -- | -- |
| Arecor Therapeutics PLC | 5.06m | -8.10m | 29.26m | 37.00 | -- | 10.25 | -- | 5.78 | -0.2208 | -0.2208 | 0.1368 | 0.0756 | 0.6482 | 18.58 | 1.93 | 136,783.80 | -103.79 | -53.69 | -187.88 | -68.26 | -2.45 | -- | -160.13 | -248.39 | 2.00 | -- | 0.0571 | -- | 10.50 | -- | -19.66 | -- | -- | -- |
| ImmuPharma PLC | 0.00 | -3.93m | 31.92m | 6.00 | -- | 94.25 | -- | -- | -0.0089 | -0.0089 | 0.00 | 0.0007 | 0.00 | -- | -- | 0.00 | -139.44 | -89.81 | -259.88 | -121.17 | -- | -- | -- | -9,895.75 | -- | -2.76 | 0.00 | -- | -- | -- | 15.00 | -- | -56.60 | -- |
| Poolbeg Pharma PLC | 0.00 | -5.71m | 32.07m | 10.00 | -- | 2.69 | -- | -- | -0.0114 | -0.0114 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -45.01 | -- | -46.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -47.29 | -- | -- | -- |
| hVIVO PLC | 51.28m | 5.28m | 41.56m | 301.00 | 7.87 | 0.9527 | 4.64 | 0.8106 | 0.0077 | 0.0077 | 0.0748 | 0.0635 | 0.5914 | -- | 3.32 | 170,362.10 | 6.09 | 5.51 | 9.53 | 10.35 | -- | -- | 10.30 | 6.73 | 1.53 | -- | 0.2521 | 66.99 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
Data as of Feb 10 2026. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX
12.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Jan 2026 | 8.35m | 6.05% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Jan 2026 | 6.14m | 4.45% |
| KW Investment Management Ltd.as of 01 Jan 2026 | 1.16m | 0.84% |
| IG Markets Ltd.as of 01 Jan 2026 | 614.00k | 0.45% |
| Eurizon Capital SGR SpAas of 01 Jan 2026 | 486.00k | 0.35% |
| Rowan Dartington & Co. Ltd. (Broker)as of 01 Jan 2026 | 278.00k | 0.20% |
| HSBC Bank Plc (Market-Maker)as of 01 Jan 2026 | 249.00k | 0.18% |
| Evelyn Partners Investment Management Services Ltd.as of 01 Jan 2026 | 202.00k | 0.15% |
| Rathbones Investment Management Ltd.as of 01 Jan 2026 | 182.00k | 0.13% |
| J. M. Finn & Co. Ltd.as of 01 Jan 2026 | 117.00k | 0.09% |
More ▼
Data from 31 Mar 2025 - 04 Feb 2026Source: FactSet Research Systems Inc.
